Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient

Ceftazidime/avibactam (CAZ-AVI) is currently endorsed as first-line treatment for CPE-related infections, due to its in vitro activity, safety profile, and lack of other feasible options (Zhanel et al. 2013).

Source: International Journal of Infectious Diseases - October 14, 2021 Category: Infectious Diseases Authors: Paolo Gaibani, Milo Gatti, Matteo Rinaldi, Cristina Crovara, Tiziana Lazzarotto, Maddalena Giannella, Donatella Lombardo, Stefano Amadesi, Pierluigi Viale, Federico Pea, Simone Ambretti Tags: Case report Source Type: research